INS and Insulin resistance: The mean (95% CI) changes from the baseline values in HOMA-R at the end of the treatment period were 0.22 (−1.09–1.52) in the azilsartan group and −0.23 (−0.72–0.27) in the telmisartan group, thus indicating that azilsartan and telmisartan did not clinically remarkably improve insulin resistance, although telmisartan showed a trend of slightly decreasing insulin sensitivity.